Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24439555)

1.

The cytokine model of schizophrenia: emerging therapeutic strategies.

Girgis RR, Kumar SS, Brown AS.

Biol Psychiatry. 2014 Feb 15;75(4):292-9. doi: 10.1016/j.biopsych.2013.12.002. Epub 2013 Dec 11. Review.

2.

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery.

Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR.

Mol Psychiatry. 2014 Jan;19(1):20-9. doi: 10.1038/mp.2013.136. Epub 2013 Oct 29. Review.

PMID:
24166406
3.

Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia?

Kato TA, Monji A, Mizoguchi Y, Hashioka S, Horikawa H, Seki Y, Kasai M, Utsumi H, Kanba S.

Mini Rev Med Chem. 2011 Jun;11(7):565-74. Review.

PMID:
21699487
4.

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S.

Curr Pharm Des. 2009;15(22):2550-9. Review.

5.

Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis.

Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, Daskalakis ZJ.

Schizophr Res. 2012 Sep;140(1-3):214-20. doi: 10.1016/j.schres.2012.06.027. Epub 2012 Jul 12.

PMID:
22795368
6.

Cytokines and schizophrenia: Microglia hypothesis of schizophrenia.

Monji A, Kato T, Kanba S.

Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65. Review.

PMID:
19579286
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Miyamoto S, Duncan GE, Marx CE, Lieberman JA.

Mol Psychiatry. 2005 Jan;10(1):79-104. Review.

PMID:
15289815
9.

Cytokines in schizophrenia and the effects of antipsychotic drugs.

Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS.

Brain Behav Immun. 2006 Nov;20(6):532-45. Epub 2006 Apr 3. Review.

PMID:
16580814
10.

The potential role of lamotrigine in schizophrenia.

Large CH, Webster EL, Goff DC.

Psychopharmacology (Berl). 2005 Sep;181(3):415-36. Epub 2005 Oct 12. Review.

PMID:
16001126
11.

Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

Noetzel MJ, Jones CK, Conn PJ.

Discov Med. 2012 Nov;14(78):335-43. Review.

12.

The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs.

Arolt V, Ambrée O.

Mod Trends Pharmacopsychiatri. 2013;28:100-16. doi: 10.1159/000343972. Epub 2013 Feb 27. Review.

PMID:
25224894
13.

Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Paz RD, Tardito S, Atzori M, Tseng KY.

Eur Neuropsychopharmacol. 2008 Nov;18(11):773-86. doi: 10.1016/j.euroneuro.2008.06.005. Epub 2008 Jul 23. Review.

14.

Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models.

Watanabe Y, Someya T, Nawa H.

Psychiatry Clin Neurosci. 2010 Jun;64(3):217-30. doi: 10.1111/j.1440-1819.2010.02094.x. Review.

PMID:
20602722
15.
16.

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK.

Biol Psychiatry. 2014 Mar 1;75(5):e11-3. doi: 10.1016/j.biopsych.2013.06.011. Epub 2013 Jul 25. No abstract available.

PMID:
23890739
17.

Schizophrenia and the immune system: pathophysiology, prevention, and treatment.

Richard MD, Brahm NC.

Am J Health Syst Pharm. 2012 May 1;69(9):757-66. doi: 10.2146/ajhp110271. Review.

PMID:
22517021
18.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
19.

Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.

Sanyal S, Van Tol HH.

J Psychiatr Res. 1997 Mar-Apr;31(2):219-32. Review.

PMID:
9278187
20.

DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia.

Abdolmaleky HM, Nohesara S, Ghadirivasfi M, Lambert AW, Ahmadkhaniha H, Ozturk S, Wong CK, Shafa R, Mostafavi A, Thiagalingam S.

Schizophr Res. 2014 Feb;152(2-3):373-80. doi: 10.1016/j.schres.2013.12.007. Epub 2014 Jan 8.

PMID:
24411530
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk